Thai Breast Disease Society

06/10/2026

ABC 8 provides updated, globally applicable guidance for personalised advanced breast cancer management while highlighting the need to address inequalities in access to high-quality care.

06/10/2026

Among patients with ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery, negative surgical margins narrower than 2 mm were not associated with a significantly higher risk of ipsilateral recurrence compared with margins of at least 2 mm—except among patients younger than age 50—according to findings from a large patient-level analysis reported by Nash et al in the Journal of Clinical Oncology.

06/10/2026

Immune-rich tumor microenvironments predict better ICI outcomes, whereas fibrovascular and myeloid remodeling appear to drive resistance in advanced TNBC.

06/10/2026

Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer experienced significantly improved progression-free survival when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach. These findings, from the phase III evERA Breast Cancer study, were published by Mayer et al in The New England Journal of Medicine.

Giredestrant and everolimus target the estrogen receptor (ER) pathway and the phosphatidylinositol 3-kinase (PI3K)–protein kinase B (AKT)–mammalian target of rapamycin (mTOR) pathway, respectively,...

29/09/2026

For years, the standard recommendation for breast cancer returning in the same breast after initial lumpectomy and radiation (ipsilateral breast tumor recurrence) was a full salvage mastectomy. But a new real-world study published in The Oncologist shows that total breast removal isn't always necessary!

AbstractBackground. Salvage mastectomy has long been regarded as the standard treatment for ipsilateral breast tumor recurrence (IBTR) after initial breast

29/09/2026

The 11th Korean Breast Cancer Society Consensus Conference on Axillary Management in Early Breast Cancer: Meeting Highlights.

Bae SJ, et al. J Breast Cancer. 2026 Aug;29(4):313-323. https://doi.org/10.4048/jbc.2026.0144

29/09/2026

A recent study published in the International Journal of Surgery provides major insights into surgical de-escalation—meaning less invasive treatments with the same great outcomes—for patients undergoing mastectomies.

22/09/2026

Genomic testing may be particularly important in older patients with MBC because age is associated with distinct, potentially targetable molecular alterations.

22/09/2026

Can weight-loss drugs like GLP-1s actually lower breast cancer risk?: 2026 ASCO UPDATE

1️⃣ Lower Incidence & Risk
GLP-1 use is linked to a 16% reduction in breast cancer risk among high-risk women with obesity. This protective trend is most prominent in postmenopausal women, patients with a BMI > 40, and those with a history of benign breast lesions.

2️⃣ Decreased Detection Rates
Recent screening data reveals that women actively using GLP-1s had significantly lower rates of breast cancer detection compared to non-users (1.6% vs. 2.3–2.6%).

3️⃣ Better Survival & Clinical Outcomes
For patients already diagnosed with early-stage breast cancer, those on GLP-1s demonstrated a notably higher 5-year overall survival rate (95.8% vs. 91.3%). Even more impressively, the rate of progressing to metastatic disease (Stage IV) was cut in half (10% vs. 20%) compared to patients on other metabolic medications.

📌 The Bottom Line:
While this observational data is highly promising, we cannot confirm direct causality just yet. We are awaiting randomized clinical trials to determine if this anti-cancer effect comes directly from the medication, or if it is a secondary benefit of improved metabolic health and weight loss.

Ref:
1. Gotera NP, Jones C, Gelfond J, et al: GLP-1 receptor agonists for primary prevention of breast cancer in high-risk women: A real-world analysis of efficacy and safety. 2026 ASCO Annual Meeting. Abstract 10520. Presented June 1, 2026.

2. McDonald ES, Gillis L, Gabriel P, et al: Association of GLP-1 agonists with breast cancer incidence in women. 2026 ASCO Annual Meeting. Abstract 10506. Presented June 2, 2026.

3. Sukumar JS, Niu J, Jackson I, et al: Real-world treatment patterns and mortality associated with GLP1-RAs in breast cancer patients. 2026 ASCO Annual Meeting. Abstract 629. Presented June 1, 2026.

01/09/2026

Because Triple-Negative Breast Cancer is highly complex and heterogeneous, predicting patient outcomes after comprehensive treatment can be challenging. A new study published in Frontiers in Oncology (August 2026) explores how specific molecular subtypes can help predict survival in TNBC patients treated with neoadjuvant chemotherapy (NAC), surgery, and radiotherapy.

BackgroundTriple-negative breast cancer (TNBC) is known for its heterogeneity. Due to the small sample sizes in prior studies, there is limited understanding...